The Measurement of Multifactorial Thrombophilia

• References

• 1 Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia. Part I. Thromb Haemost 1996; 76: 651-2.
• 2 Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost 2001; 86: 395-403.
• 3 Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost 1997; 78: 297-301.
• 4 Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden. Lancet 1994; 344: 1453-7.
• 5 Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-3.
• 6 Robert A, Eschwage V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon contortrix venom (AVC test) : a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-6.
• 7 Tripodi A, Akhavan S, Asti D, Faioni EM, Mannucci PM. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway. Blood Coagul Fibrinolysis 1998; 09: 485-9.
• 8 Rosendaal FR, van der Meer FJ, de Visser MC, Wagner C. ProcC global screening test and the risk of thrombosis. Thromb Haemost 1999; suppl. 731.
• 9 Curvers J, Thomassen MCLGD, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a tissue-factor based APC-resistance test. Thromb Haemost 2002; 88: 5-11.
• 10 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay process. Thromb Haemost 1986; 56: 9-17.
• 11 Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
• 12 Rosing J, Middeldorp S, Curvers J, Thomassen MCLGD, Nicolaes GAF, Meijers JC, Bouma BN, Buller HR, Prins MH, Tans G. Low dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study. Lancet 1999; 354: 2036-40.
• 13 Rottevell RC, Roozendaal KJ, Eijsman L, Hemker HC. The influence of oral contraceptives on the time integral of thrombin generation (thrombin potential). Thromb Haemost 1993; 70: 959-62.
• 14 Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
• 15 Wielders S, Mukherjee M, Michiels J, Rijkers DT, Cambus JP, Knebel RWC, Kakkar V, Hemker HC, Beguin S. The routine determination of the endogenous thrombin potential, first results in different forms of hyper-and hypocoagulability. Thromb Haemost 1997; 77: 629-36.
• 16 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
• 17 Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001; 47: 1597-1606.